Sinclair Research, a US-based biomedical research company, has appointed Mark Lane as its director of business development. Lane will have responsibility for the San Francisco to Seattle corridor. He will be responsible for driving the growth of Sinclair’s IND enabling toxicology and efficacy models and fostering positive relationships with new and current customers.
Lane joins Sinclair with more than 25 years of experience in the contract research organisation (CRO) industry. He has extensive experience in DMPK, safety pharmacology, experimental therapeutics and molecular imaging.
“Sinclair is fortunate to recruit such an outstanding industry veteran. Mark’s industry knowledge and welcoming style are a great fit for our company and our market,” said Mark Crane, vice president of business development.
Lane has been published in various journals and is an active member of professional organizations, including the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society for Whole-Body Autoradiography (SWBA), American Association for Cancer Research (AACR) and American College of Toxicology (ACT). His preclinical market knowledge and experience from the pharmaceutical and CRO industries will be of significant value to Sinclair and all its customers.
